
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics is making steady progress with their elraglusib treatment for pediatric neuroblastoma, with an upcoming dose-confirmation cohort of 20 patients expected to define key metrics for the drug's use in combination with dinutuximab beta and chemotherapy. If approved, this could make Actuate eligible for a rare pediatric disease Priority Review Voucher, which could have a significant financial impact. Early preclinical data also supports continued development of intravenous elraglusib in multiple pediatric orphan oncology indications, and if successful, the drug could be eligible for a PRV upon approval.
Bears say
Actuate Therapeutics is facing a significant challenge in the high costs of product development, and a potential decrease in their cash flow due to the change in fair value of warrant liabilities. Despite upcoming preclinical data that may support combination use with RAS inhibitors, the company is still in early stages and facing uncertainty in their potential benefits from the combination therapy. Investors should approach this stock with caution, keeping in mind the company's current financial challenges and the lack of solid clinical data at this time.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares